MErCuRIC1: A Phase I study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in RASMT and RASWT (with aberrant c-MET) metastatic colorectal cancer (mCRC) patients.
SCHAEYBROECK, Van; S ROLFO; CD ELEZ; E KELLY; S HOULDEN et al.
MErCuRIC1: A Phase I study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in RASMT and RASWT (with aberrant c-MET) metastatic colorectal cancer (mCRC) patients.
Autoři
SCHAEYBROECK, Van; S ROLFO; CD ELEZ; E KELLY; S HOULDEN; J COLLINS; L LOVE; S ANDRE; T LAWLER; M Di NICOLANTONIO; F GRAYSON; Vlad POPOVICI; VC BARDELLI; A LAURENT-PUIG; P SALTO-TELLEZ; M MAUGHAN; T TABERNERO; J PEETERS; M WILSON; RH MIDDLETON a MR
Vydání
Journal of clinical oncology, 2318 MILL ROAD, STE 800, ALEXANDRIA, VA, AMER SOC CLINICAL ONCOLOGY, 2015, 0732-183X
SCHAEYBROECK, Van; S ROLFO; CD ELEZ; E KELLY; S HOULDEN; J COLLINS; L LOVE; S ANDRE; T LAWLER; M Di NICOLANTONIO; F GRAYSON; Vlad POPOVICI; VC BARDELLI; A LAURENT-PUIG; P SALTO-TELLEZ; M MAUGHAN; T TABERNERO; J PEETERS; M WILSON; RH MIDDLETON a MR. MErCuRIC1: A Phase I study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in RASMT and RASWT (with aberrant c-MET) metastatic colorectal cancer (mCRC) patients. Journal of clinical oncology. 2318 MILL ROAD, STE 800, ALEXANDRIA, VA: AMER SOC CLINICAL ONCOLOGY, 2015, roč. 33, č. 15, s. "Amer Soc Clin Oncol"-"0", 1 s. ISSN 0732-183X. Dostupné z: https://doi.org/10.1200/jco.2015.33.15_suppl.tps3632.
@article{1392213, author = {Schaeybroeck, Van and Rolfo, S and Elez, CD and Kelly, E and Houlden, S and Collins, J and Love, L and Andre, S and Lawler, T and Nicolantonio, M Di and Grayson, F and Popovici, Vlad and Bardelli, VC and LaurentandPuig, A and SaltoandTellez, P and Maughan, M and Tabernero, T and Peeters, J and Wilson, M and Middleton, RH and MR, }, article_location = {2318 MILL ROAD, STE 800, ALEXANDRIA, VA}, article_number = {15}, doi = {https://doi.org/10.1200/jco.2015.33.15_suppl.tps3632}, language = {eng}, issn = {0732-183X}, journal = {Journal of clinical oncology}, title = {MErCuRIC1: A Phase I study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in RASMT and RASWT (with aberrant c-MET) metastatic colorectal cancer (mCRC) patients.}, url = {http://dx.doi.org/10.1200/jco.2015.33.15_suppl.tps3632}, volume = {33}, year = {2015} }
TY - JOUR ID - 1392213 AU - Schaeybroeck, Van - Rolfo, S - Elez, CD - Kelly, E - Houlden, S - Collins, J - Love, L - Andre, S - Lawler, T - Nicolantonio, M Di - Grayson, F - Popovici, Vlad - Bardelli, VC - Laurent-Puig, A - Salto-Tellez, P - Maughan, M - Tabernero, T - Peeters, J - Wilson, M - Middleton, RH - MR, PY - 2015 TI - MErCuRIC1: A Phase I study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in RASMT and RASWT (with aberrant c-MET) metastatic colorectal cancer (mCRC) patients. JF - Journal of clinical oncology VL - 33 IS - 15 SP - "Amer Soc Clin Oncol"-"0" EP - "Amer Soc Clin Oncol"-"0" PB - AMER SOC CLINICAL ONCOLOGY SN - 0732183X UR - http://dx.doi.org/10.1200/jco.2015.33.15_suppl.tps3632 L2 - http://dx.doi.org/10.1200/jco.2015.33.15_suppl.tps3632 ER -
SCHAEYBROECK, Van; S ROLFO; CD ELEZ; E KELLY; S HOULDEN; J COLLINS; L LOVE; S ANDRE; T LAWLER; M Di NICOLANTONIO; F GRAYSON; Vlad POPOVICI; VC BARDELLI; A LAURENT-PUIG; P SALTO-TELLEZ; M MAUGHAN; T TABERNERO; J PEETERS; M WILSON; RH MIDDLETON a MR. MErCuRIC1: A Phase I study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in RASMT and RASWT (with aberrant c-MET) metastatic colorectal cancer (mCRC) patients. \textit{Journal of clinical oncology}. 2318 MILL ROAD, STE 800, ALEXANDRIA, VA: AMER SOC CLINICAL ONCOLOGY, 2015, roč.~33, č.~15, s.~''Amer Soc Clin Oncol''-''0'', 1 s. ISSN~0732-183X. Dostupné z: https://doi.org/10.1200/jco.2015.33.15\_{}suppl.tps3632.